Compare CVBF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVBF | RYTM |
|---|---|---|
| Founded | 1974 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 5.9B |
| IPO Year | 2009 | 2017 |
| Metric | CVBF | RYTM |
|---|---|---|
| Price | $19.53 | $86.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $24.17 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.2M | 945.1K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | 5.56 | ★ 28.34 |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.47 | $55.17 |
| Revenue Next Year | $15.21 | $95.98 |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.01 | $45.91 |
| 52 Week High | $21.48 | $122.20 |
| Indicator | CVBF | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 49.59 |
| Support Level | $19.18 | $84.39 |
| Resistance Level | $20.62 | $97.19 |
| Average True Range (ATR) | 0.44 | 5.47 |
| MACD | 0.10 | 0.71 |
| Stochastic Oscillator | 82.81 | 54.25 |
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.